Global Patent Index - EP 1850872 A4

EP 1850872 A4 20081015 - A METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION

Title (en)

A METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION

Title (de)

VERFAHREN ZUR VERWENDUNG EINES ANTI-CD-137-ANTIKÖRPERS ALS MITTEL FÜR DIE RADIOIMMUNTHERAPIE ODER DEN RADIOIMMUN-NACHWEIS

Title (fr)

PROCEDE D'UTILISATION D'UN ANTICORPS ANTI-CD137 EN TANT QU'AGENT DE RADIO-IMMUNOTHERAPIE OU RADIO-IMMUNODETECTION

Publication

EP 1850872 A4 20081015 (EN)

Application

EP 05723386 A 20050218

Priority

  • US 2005005405 W 20050218
  • US 5845805 A 20050215
  • US 2005004739 W 20050215

Abstract (en)

[origin: WO2006088464A2] The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.

IPC 8 full level

A61K 39/395 (2006.01); C07K 16/00 (2006.01)

CPC (source: EP)

A61K 47/6817 (2017.07); A61K 47/6829 (2017.07); A61K 47/6849 (2017.07); A61K 51/1027 (2013.01); C07K 16/2878 (2013.01); A61K 2039/507 (2013.01); C07K 2317/12 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01)

Citation (search report)

  • [A] MILLER ROBERT E ET AL: "4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 AUG 2002, vol. 169, no. 4, 15 August 2002 (2002-08-15), pages 1792 - 1800, XP001180752, ISSN: 0022-1767
  • See references of WO 2006088464A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2006088464 A2 20060824; WO 2006088464 A3 20071115; EP 1850872 A2 20071107; EP 1850872 A4 20081015

DOCDB simple family (application)

US 2005005405 W 20050218; EP 05723386 A 20050218